CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 2.78: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.17BUSDvs all stocks (USD)
Revenue (TTM)
177.68MUSDvs all stocks (USD)
Profit Margin
-20.67%Beta
0.5400xvs all stocks
52-Week Change
173.00%vs all stocks
Market Capitalization
1.17BUSDvs all stocks (USD)
Enterprise Value
1.35BUSDvs all stocks (USD)
Forward P/E
124.67xPrice to Sales (TTM)
6.28xPrice to Book (MRQ)
14.42xEnterprise to Revenue
7.59xEnterprise to EBITDA
-124.16xGross Margin
33.99%Profit Margin
-20.67%Operating Margin
-35.42%Return on Assets (TTM)
-5.27%Return on Equity (TTM)
-20.43%Revenue (TTM)
177.68MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.13USDUpdated Jul 9, 2026Quarterly Revenue Growth
-9.60%Gross Profit (TTM)
66.91MUSDvs all stocks (USD)
EBITDA (TTM)
10.07MUSDvs all stocks (USD)
Net Income (TTM)
-50.44MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-13.30%Operating Cash Flow (TTM)
-2.78MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-26.13MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 9, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Minority Interest (Equity)
23.17MUSDFY2025 · Dec 31, 2025Revenue
181.98MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
105.02MUSDFY2025 · Dec 31, 2025Gross Profit
76.96MUSDFY2025 · Dec 31, 2025Operating Income
-14.63MUSDvs all stocks (USD)
Pre-tax Income
-17.02MUSDFY2025 · Dec 31, 2025Income Tax Expense
11.93MUSDFY2025 · Dec 31, 2025Net Income
-28.95MUSDFY2025 · Dec 31, 2025EBIT
-9.96MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
10.07MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
75.83MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
288.00KUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
7.06MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.3607USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.3607USDFY2025 · Dec 31, 2025Basic Shares Outstanding
80.26MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
80.26MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-28.95MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
-707.00KUSDFY2025 · Dec 31, 2025Operating Cash Flow
8.62MUSDFY2025 · Dec 31, 2025Free Cash Flow
-18.56MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
23.35MUSDFY2025 · Dec 31, 2025Income Tax Paid
2.46MUSDFY2025 · Dec 31, 2025Interest Paid
4.53MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-28.95MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
15.76MUSDFY2025 · Dec 31, 2025Stock-based Compensation
13.40MUSDFY2025 · Dec 31, 2025Other Non-cash Items
969.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
591.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
5.82MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
1.03MUSDFY2025 · Dec 31, 2025Capital Expenditures
-27.18MUSDFY2025 · Dec 31, 2025Other Investing Activity
-563.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-27.74MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
52.10MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-43.91MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-18.50MUSDFY2025 · Dec 31, 2025Common Dividends Paid
-8.30MUSDFY2025 · Dec 31, 2025Other Financing Charges
-342.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
1.72MUSDFY2025 · Dec 31, 2025Shares Outstanding
84.66MSharesUpdated Jul 9, 2026Float Shares
65.66MSharesUpdated Jul 9, 2026% Held by Insiders
8.65%vs all stocks
% Held by Institutions
6.55%vs all stocks
Total Cash (MRQ)
24.43MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.2880USDUpdated Jul 9, 2026Total Debt (MRQ)
75.05MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.4229xCurrent Ratio (MRQ)
1.85xBook Value per Share (MRQ)
0.9080USDUpdated Jul 9, 2026Total Assets
318.56MUSDvs all stocks (USD)
Total Current Assets
67.75MUSDFY2025 · Dec 31, 2025Total Liabilities
221.46MUSDFY2025 · Dec 31, 2025Total Non-current Assets
250.81MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
183.50MUSDFY2025 · Dec 31, 2025Total Current Liabilities
37.96MUSDFY2025 · Dec 31, 2025Cash
19.85MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
19.85MUSDFY2025 · Dec 31, 2025Accounts Receivable
4.42MUSDFY2025 · Dec 31, 2025Inventory
26.23MUSDFY2025 · Dec 31, 2025Accounts Payable
13.71MUSDFY2025 · Dec 31, 2025Short-term Debt
1.99MUSDFY2025 · Dec 31, 2025Long-term Debt
72.58MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
33.41MUSDFY2025 · Dec 31, 2025Common Stock (Book)
0.00USDFY2025 · Dec 31, 2025Retained Earnings
-220.07MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
97.10MUSDvs all stocks (USD)
52-Week Low
4.55USDUpdated Jul 9, 202652-Week High
13.92USDUpdated Jul 9, 202652-Week Change
173.00%vs all stocks
Beta
0.5400xvs all stocks
50-Day MA
10.29USDUpdated Jul 9, 2026200-Day MA
8.48USDUpdated Jul 9, 2026Avg 10-Day Volume
254.41KSharesUpdated Jul 9, 2026Avg 30-Day Volume
258.22KSharesUpdated Jul 9, 2026Diluted EPS (TTM)
-0.6500USDUpdated Jul 9, 2026Other Income / Expense
4.38MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 2.78: safe zoneNotable
Altman Z-Score: 2.78
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Avanos Medical Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sanofi Consumer Healthcare Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Replimune Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Winsunny Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tianjin Ringpu Bio-Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Warrants Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beta Bionics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Innovita Biological Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Novogene Co., Ltd.
Tier 1ProductionApproval-Gated PipelineSenseMakingFlow
Harbin Gloria Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule